Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.45 |
| ▸ | FLT1 | P17948 | 8/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230591 | 0.93 | HPGDS (0.45) | HPGDSSLC22A12TGFBR1TGFBR2NPC1 | |
| SCHEMBL3226785 | 0.90 | HPGDS (0.46) | HPGDSFLT1KDRTGFBR1TGFBR2 | |
| SCHEMBL3213056 | 0.85 | HPGDS (0.47) | HPGDSFLT1KDRSLC22A12NPC1 | |
| SCHEMBL14313107 | 0.85 | SLC22A12 (0.33) | HPGDSFLT1KDRSLC22A12TGFBR1 | |
| SCHEMBL3210289 | 0.83 | HPGDS (0.45) | HPGDSKDRSLC22A12CHRM1 | |
| SCHEMBL3226481 | 0.83 | HPGDS (0.46) | HPGDSTGFBR1TGFBR2NPC1RAB9A | |
| SCHEMBL3219653 | 0.78 | HPGDS (0.34) | HPGDSSLC22A12NPC1RAB9ACHRM1 | |
| SCHEMBL14312739 | 0.78 | SLC22A12 (0.33) | HPGDSSLC22A12TGFBR1TGFBR2 | |
| SCHEMBL3222736 | 0.78 | HPGDS (0.47) | HPGDSSLC22A12NPC1RAB9A | |
| SCHEMBL14313094 | 0.77 | TGFBR1 (0.35) | HPGDSSLC22A12TGFBR1TGFBR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885FLT1 777/4885KDR 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.